You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Investigational Drug Information for Vorasidenib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Vorasidenib?

Vorasidenib is an investigational drug.

There have been 6 clinical trials for Vorasidenib. The most recent clinical trial was a Phase 1 trial, which was initiated on January 5th 2020.

The most common disease conditions in clinical trials are Glioma, Liver Diseases, and Astrocytoma. The leading clinical trial sponsors are Institut de Recherches Internationales Servier, Agios Pharmaceuticals, Inc., and Katy Peters, MD, PhD.

There are six US patents protecting this investigational drug and eighty-four international patents.

Recent Clinical Trials for Vorasidenib
TitleSponsorPhase
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsInstitut de Recherches Internationales ServierPhase 1
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsServier Bio-Innovation LLCPhase 1
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionInstitut de Recherches Internationales ServierPhase 1

See all Vorasidenib clinical trials

Clinical Trial Summary for Vorasidenib

Top disease conditions for Vorasidenib
Top clinical trial sponsors for Vorasidenib

See all Vorasidenib clinical trials

US Patents for Vorasidenib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vorasidenib ⤷  Sign Up Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
Vorasidenib ⤷  Sign Up Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
Vorasidenib ⤷  Sign Up Methods of treating brain tumors using combination therapy Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign Up
Vorasidenib ⤷  Sign Up ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vorasidenib

Drugname Country Document Number Estimated Expiration Related US Patent
Vorasidenib Argentina AR096902 2033-07-11 ⤷  Sign Up
Vorasidenib Australia AU2014289744 2033-07-11 ⤷  Sign Up
Vorasidenib Australia AU2019201179 2033-07-11 ⤷  Sign Up
Vorasidenib Brazil BR112016000561 2033-07-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.